Released Nov 14, 2018, after the close
10-Q filed Nov 14, 2018, 45 days after period end · 0001390478-18-000035
Q3 2018 · 10-Q
Revenue—
Net Income-$290.00K-$290.00K N/M vs Q3 2017N/M vs Q2 2018
EPS Diluted-$26.75-$26.75 N/M vs Q3 2017N/M vs Q2 2018
Operating Cash Flowderived-$14,165,000N/M
What the release said
The release
Same quarter
| Metric | Q3 2018 | Q3 2017 | Q3 2016 | Q3 2013 |
|---|---|---|---|---|
| Revenue | — | — | — | $2.17M |
| Net Income | -$290.00K | -$4.46M | -$6.93M | -$6.93M |
| EPS Diluted | -$26.75 | -$2.27 | — | -$0.11 |
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
SELLAS Life Sciences Group, Inc. · CIK 1390478 · Engraved from SEC EDGAR